Sultan Linjawi
Overview
Explore the profile of Sultan Linjawi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harris S, Abrahamson M, Ceriello A, Charpentier G, Evans M, Lehmann R, et al.
Drugs
. 2020 Jan;
80(2):147-165.
PMID: 31960258
Therapeutic inertia is a substantial obstacle to the initiation of insulin therapy in people with uncontrolled type 2 diabetes (T2D). This effect has in part been perpetuated by concerns over...
2.
Lingvay I, Handelsman Y, Linjawi S, Vilsboll T, Halladin N, Ranc K, et al.
Endocr Pract
. 2018 Nov;
25(2):144-155.
PMID: 30383495
Objective: The efficacy and safety of insulin degludec/liraglutide (IDegLira) in older patients has not yet been reported. This analysis aimed to evaluate the efficacy and safety of IDegLira in patients...
3.
Liebl A, Mohan V, Yang W, Strojek K, Linjawi S
Drugs R D
. 2018 Feb;
18(1):27-39.
PMID: 29468559
Since clinical experience with biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes mellitus (T2DM) was reviewed in 2012 after 10 years of use worldwide, additional studies have been...
4.
Linjawi S, Lee B, Tabak O, Lovdahl S, Werther S, Abusnana S
Diabetes Ther
. 2017 Nov;
9(1):1-11.
PMID: 29129018
Introduction: This 32-week, open-label, randomized, parallel-group, multinational trial aimed to compare the efficacy and safety of stepwise insulin intensification of biphasic insulin aspart 30 (BIAsp 30) relative to stepwise intensification...
5.
Linjawi S, Bode B, Chaykin L, Courreges J, Handelsman Y, Lehmann L, et al.
Diabetes Ther
. 2016 Dec;
8(1):101-114.
PMID: 27943107
Introduction: The progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs (OADs) initially, followed by other agents, such as glucagon-like peptide-1 receptor...
6.
Holst J, Buse J, Rodbard H, Linjawi S, Woo V, Boesgaard T, et al.
J Diabetes Sci Technol
. 2015 Oct;
10(2):389-97.
PMID: 26443290
Objective: IDegLira is a novel, fixed-ratio combination of the long-acting basal insulin, insulin degludec, and the long-acting glucagon-like peptide-1 analog liraglutide. We studied the effect of IDegLira versus its components...
7.
Linjawi S, Sothiratnam R, Sari R, Andersen H, Hiort L, Rao P
Prim Care Diabetes
. 2014 Dec;
9(5):370-6.
PMID: 25488587
Aims: Investigate efficacy and tolerability of intensifying diabetes treatment with once- or twice-daily biphasic insulin aspart 30 (BIAsp 30) added to sitagliptin, and twice-daily BIAsp 30 without sitagliptin in patients...
8.
Gough S, Bode B, Woo V, Rodbard H, Linjawi S, Poulsen P, et al.
Lancet Diabetes Endocrinol
. 2014 Sep;
2(11):885-93.
PMID: 25190523
Background: A fixed-ratio combination of the basal insulin analogue insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide has been developed as a once-daily injection for the treatment of type...